Mohit Narang

6 days ago | ajmc.com | Hayden E. Klein |Mohit Narang

Captions were auto-generated. For patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for years, switching to zanubrutinib may offer significant advantages such as fewer cardiac events and a smoother clinical workflow, according to Mohit Narang, MD, managing partner at Maryland Oncology Hematology.

3 weeks ago | ajmc.com | Hayden E. Klein |Mohit Narang

Oncologists are increasingly opting for zanubrutinib over ibrutinib to treat patients with chronic lymphocytic leukemia (CLL) due to its improved safety profile and reduced risk of cardiovascular side effects, according to Mohit Narang, MD, managing partner at Maryland Oncology Hematology. In a recent interview with The American Journal of Managed Care® (AJMC®), Narang explained his rationale for switching his patients to the second-generation Bruton tyrosine kinase (BTK) inhibitor.